Key facts, as of
As of September 29, 2026, Elevance Health (ELV) trades at $392.73, up 22.8% over the past year. Its 52-week range runs from $274.84 to $436.24; the price is 10.0% below that high. It sits 7.5% above its 200-day average of $365.42, the usual sign of a long-term uptrend. Its 30-day volatility is 26.3% annualized, which we rate medium risk. It has a trailing P/E of 17.4 and a dividend yield of 1.74%.
Cite: Portfolio Terminal, "Elevance Health (ELV) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/elv
Where it trades today
trading 73% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ELV trades at 17.4x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 26.3%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ELV is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ELV come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ELV. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Elevance Health does
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services,…
Employees
96,129
Industry
Healthcare Plans
Headquarters
Indianapolis, United States
What analysts expect
ELV carries a buy consensus from 21 analysts, with an average price target of $451.38 versus $392.73 today (+14.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ELV generated $201.11B in trailing revenue (1.4% year over year), with a 2.5% net margin, and $4.31B of free cash flow, supported by $6.47B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $199.13B | — | — | $5.66B | $25.65 | $3.17B |
| 2024 | $176.81B | — | — | $5.98B | $26.29 | $4.55B |
| 2023 | $171.34B | — | — | $5.99B | $25.69 | $6.76B |
| 2022 | $156.59B | — | — | $5.89B | $25.32 | $7.25B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ELV beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 1.2% below its 50-day average and 7.5% above its 200-day.
- The 50-day crossed above the 200-day on 2026-05-20 (a “golden cross”).
- RSI at 41 is neither stretched nor washed out.
- The nearest ceiling is $407.67 (+3.8%), the nearest floor $382.85 (-2.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is ELV a good buy right now?
Elevance Health trades at 17.4x earnings. This is near market average. Current risk level is Medium based on 26.3% volatility.
Does ELV pay dividends?
Yes, Elevance Health offers a dividend yield of 1.74%. That is roughly $6.83 per share a year.
How volatile is ELV?
With 30-day annualized volatility of 26.3% and beta of 0.70, ELV is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for ELV?
The average analyst price target for Elevance Health (ELV) is $451.38 based on 21 analyst estimates, about 14.9% above the current price of $392.73. The published range runs from $393.00 to $492.00.
How much revenue does ELV generate?
Elevance Health reported $201.11B in trailing twelve-month revenue. Revenue growth is running at 1.4% year over year. Net margin sits at 2.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare ELV with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.